Longeveron Inc.
LGVNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeLongeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. The company carries a $21.2M market cap, placing it firmly in the micro-cap category. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
Market Cap
$21.2M
Beta
-0.26
P/E (TTM)
—
P/E (Fwd)
-4.35
EPS (TTM)
$-9.95
EPS (Fwd)
$-1.53
ROE
-203.6%
ROA
-91.0%
Cash
$10.1M
Total Debt
$581,000
Free CF
-$11.6M
52W Change
-14.9%
Annual Financials
Cash vs Debt
Where LGVN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, LGVN finished 571.29% above its 150-day moving average ($1.01) and 653.33% above its 200-day moving average ($0.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LGVN overbought or oversold?
At the September 3, 2026 close, LGVN's RSI(14) was 91.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $10.1M in cash comfortably exceeding the $581K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$11.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -203.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $1.2M (2022) to $1.2M (2025).
LGVN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, LGVN has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing LGVN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.